据悉,在第一季度业绩强之后,Vanguard和其他公司提升了CVS健康的股份,并提高了2025年利前景. Vanguard and others boosted CVS Health stakes after strong Q1 results and raised 2025 earnings outlook.

在第二季度,前卫、俄勒冈州公务员退休基金和PDS规划公司增加了其在CVS健康方面的股份,其中指出,Q1成果强劲,每股收入为1.81美元,击败估计数为0.35美元,收入逐年增加8.4%,达989.2亿美元。 Vanguard, Oregon Public Employees Retirement Fund, and PDS Planning increased their stakes in CVS Health during the second quarter, citing strong Q1 results with earnings of $1.81 per share, beating estimates by $0.35, and revenue up 8.4% year-over-year to $98.92 billion. 该公司将2025年全年收入指导提高到每股6.30至6.40美元,宣布季度股息为每股0.665美元,并维持中度购买评级,目标为79.80美元。 The company raised full-year 2025 earnings guidance to $6.30–$6.40 per share, announced a quarterly dividend of $0.665 per share, and maintains a moderate buy rating with a $79.80 target. 股票交易接近52周的最高值79.20美元,市场上限为987.9亿美元,P/E比率为21.76。 The stock trades near its 52-week high of $79.20, with a market cap of $98.79 billion and a P/E ratio of 21.76. Anne A. Finucane主任在8月20日出售了7 500股股票。 Director Anne A. Finucane sold 7,500 shares on August 20.